Press releases

Cash position of €9.3 million, and net loss down 1% to €6.3 million Strategic focus on high value-added applications in the healthcare,...

The partnership aims to co-develop and market new active ingredients for skin care. The ambition is to bring to market a first ingredient...

Dozens of strains coming from DEINOVE’s collection were selected following positive results of a screening conducted in collaboration with...

Specialist in pharmacology and preclinical studies in infectious diseases, Dr Bernard Scorneaux has led the studies of several drug...

Four directors of international standing and experts in pharmaceutical industry and antibiotics join the Board of Directors: Bernard Fanget...

DEINOVE (Alternext Paris: ALDEI), a biotech company that discovers, develops and produces high-value compounds from rare bacteria, notably...

Completion of the contribution in kind of DEINOBIOTICS’ shares to DEINOVE which now holds 100% of its subsidiary Consequential DEINOVE’s...

First patent applications coming out of DEINOBIOTICS’ research and pertaining to an innovative antibiotic structure Preparation underway to...

ADEME has validated key step 3 of the DEINOCHEM program after the performance targets were met for the production of the compounds of...